Thiogenesis Therapeutics Expands on Plans for Phase 3 Pivotal Trial of TTI-0102 in Nephropathic Cystinosis
San Diego, California--(Newsfile Corp. - November 24, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation sulfur-based prodrugs for rare mitochondrial and metabolic diseases, today announced plans to initiate a Phase 3 pivotal clinical trial of its lead compound TTI-0102 for the treatment of nephropathic cystinosis, an inherited lysosomal storage disorder requiring lifelong cystine-depleting therapy. The Company plans to submit an Investigational New Drug (IND) application in early 2026. About...
2025-11-24 9:00 AM EST
Thiogenesis Reports Positive Interim Phase 2 Trial Results for MELAS and Announces Pipeline Advancements in Leigh Syndrome and Cystinosis
San Diego, California--(Newsfile Corp. - November 4, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing sulfur-based therapeutics for pediatric diseases, predominantly those involving mitochondrial dysfunction, today announced interim results from its Phase 2 clinical trial of TTI-0102 for Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes or MELAS, which is being conducted at Radboud University in the Netherlands and CHU Angers in France. The Company also provided updates regarding its progress...
2025-11-04 9:00 AM EST
Thiogenesis Announces Extension to Investor Relations Agreement
San Diego, California--(Newsfile Corp. - October 3, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (Thiogenesis or the Company) a clinical-stage biotechnology company developing disulfides that drive the production of critically important intracellular antioxidants and other therapeutic compounds to treat unmet pediatric diseases, announces the extension of its investor relations agreement with Triomphe Holdings Ltd., doing business as Capital Analytica (Consultant) for a further 3-month term ending December 31, 2025. The original agreement was due to expire on September 30, 2025...
2025-10-03 4:00 PM EDT
Thiogenesis Reports on 2025 Annual General Meeting of Shareholders and Provides Corporate Update
San Diego, California--(Newsfile Corp. - September 11, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biopharmaceutical company developing sulfur-based therapeutics for serious pediatric diseases, today announced the results of its Annual General Meeting of Shareholders ("AGM") held on September 5, 2025, and provided a corporate update highlighting recent clinical and regulatory milestones.AGM ResultsShareholders re-elected all incumbent directors to the board to serve until the next AGM or until a successor is appointed:...
2025-09-11 9:00 AM EDT
Thiogenesis Receives Final Acceptance from TSXV for Its Over-Subscribed Non-Brokered Private Placement of Common Shares
San Diego, California--(Newsfile Corp. - August 14, 2025) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is pleased to announce that, further to its news release of August 1, 2025, it has received final acceptance from the TSX Venture Exchange for its heavily over-subscribed non-brokered private placement (the "Offering") of 5,529,066 common shares (the "Offered Shares") in the capital of the Company for gross proceeds of C$4,146,800 at a price of C$0.75 per Offered Share.In connection with the...
2025-08-14 8:00 AM EDT
Thiogenesis Raises over C$4.14 Million in Non-Brokered Private Placement of Common Shares
San Diego, California--(Newsfile Corp. - August 1, 2025) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is pleased to announce that, further to its news releases of July 17 and July 29, 2025, it has closed a heavily over-subscribed non-brokered private placement (the "Offering") through the issuance of 5,529,066 common shares (the "Offered Shares") in the capital of the Company for gross proceeds of C$4,146,800 at a price of C$0.75 per Offered Share.All securities issued and issuable in...
2025-08-01 8:00 AM EDT
Thiogenesis Upsizes Fully Subscribed Non-Brokered Private Placement of Common Shares
San Diego, California--(Newsfile Corp. - July 29, 2025) - Further to its news release of July 17, 2025, Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is very pleased to announce that, due to overwhelming investor demand, it has increased the size of a previously announced non-brokered private placement (the "Offering") from 2 million to 5.3 common shares of the Company (the "Offered Shares") at a price of $0.75 per Common Share for gross proceeds of approximately $4 million.This...
2025-07-29 8:00 AM EDT
Thiogenesis Announces Non-Brokered Private Placement of Common Shares
San Diego, California--(Newsfile Corp. - July 17, 2025) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") announced today that it will undertake a non-brokered private placement (the "Offering") of 2,000,000 common shares of the Company ("Offered Shares") at a price of $0.75 per Common Share for gross proceeds of $1.5 million.This Offering is subject to the approval of the TSX Venture Exchange (the "Exchange"). The Company anticipates closing of the Offering as soon as practicable subject to receipt...
2025-07-17 9:00 AM EDT
Thiogenesis Receives Confirmatory Guidance on IMPD for Pediatric MASH Phase 2a Clinical Trial in Europe and Core Patent Granted in EU
San Diego, California--(Newsfile Corp. - June 25, 2025) - Thiogenesis Therapeutics, Inc. (TSXV: TTI) (OTCQX: TTIPF), a clinical-stage biopharmaceutical company developing next-generation thiol-based therapies for mitochondrial disease and pediatric metabolic conditions, today announced that the Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency ("EMA") has provided scientific advice supporting the company's submission of an Investigational Medicinal Product Dossier ("IMPD") for a Phase 2a clinical trial in pediatric patients with metabolic dysfunction-associated steatohepatitis ("MASH").This exploratory...
2025-06-25 9:00 AM EDT
Thiogenesis Therapeutics to Present at UMDF's Mitochondrial Medicine 2025 Conference
San Diego, California--(Newsfile Corp. - June 20, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biopharmaceutical company developing sulfur-based therapeutics for rare pediatric and inherited mitochondrial disorders, today announced that its Chief Executive Officer, Patrice Rioux, MD, Ph.D., will participate in a high-profile clinical panel discussion at the United Mitochondrial Disease Foundation's ("UMDF") 2025 Mitochondrial Medicine Conference. The session is scheduled for Friday, June 20, 2025, in St. Louis, Missouri.The UMDF Mitochondrial Medicine...
2025-06-20 9:00 AM EDT
Thiogenesis Announces Second Site Begins Enrolling in Phase 2 MELAS Clinical Trial and Provides Update
San Diego, California--(Newsfile Corp. - June 17, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biopharmaceutical company developing sulfur-based therapeutics for serious pediatric and inherited mitochondrial diseases, today announced the recent activation of its French clinical site for Thiogenesis' ongoing Phase 2 clinical trial evaluating TTI-0102 in patients with Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like Episodes ("MELAS").The first patient at Angers University Hospital Center ("CHU Angers") was dosed last week, marking a...
2025-06-17 9:00 AM EDT
Thiogenesis Announces Grant of Stock Options
San Diego, California--(Newsfile Corp. - June 12, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that drive the production of critically important intracellular antioxidants and other therapeutic compounds, announces that pursuant to the terms of the Company's Omnibus Equity Incentive Plan, on June 11, 2025, the Company's board of directors approved a total grant of 400,000 common share purchase options exercisable at $0.77 to two directors of the Company....
2025-06-12 10:01 AM EDT
Thiogenesis Announces FDA Clearance of its Investigational New Drug Application ("IND") for a Phase 2a Clinical Trial in Leigh Syndrome Spectrum
San Diego, California--(Newsfile Corp. - June 11, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ('Thiogenesis' or the 'Company') a clinical-stage biotechnology company developing disulfides that drive the production of intracellular cysteine, an amino acid that is a critical precursor to the generation of the master antioxidant glutathione and other important therapeutic compounds, today announced that the U.S. Food and Drug Administration ("FDA") has cleared the Company's Investigational New Drug application ("IND") for TTI-0102, for the treatment of...
2025-06-11 9:00 AM EDT
Thiogenesis Initiates Phase 2 Clinical Trial in Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like Episodes ("MELAS")
San Diego, California--(Newsfile Corp. - May 14, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that drive the production of critically important intracellular antioxidants and other therapeutic compounds, today announced that it has dosed its first two patients in its Phase 2 clinical trial of TTI-0102, Thiogenesis' lead product candidate for the potential treatment of the inherited mitochondrial disease MELAS. The first two patients were dosed on May 12th,...
2025-05-14 9:00 AM EDT
Thiogenesis Announces European Consulting and Investor Relations Agreement
San Diego, California--(Newsfile Corp. - February 20, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that drive the production of critically important intracellular antioxidants and other therapeutic compounds, today announced that it has entered into a consulting and investor relations agreement effective February 15, 2025 (the "Agreement") with Bull Markets Media GmbH (the "Consultant"), a Germany-based digital stock market news portal.The services to be provided by the Consultant include...
2025-02-20 9:00 AM EST
Thiogenesis Announces Commencement of OTCQX Trading in the U.S.
San Diego, California--(Newsfile Corp. - February 12, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that drive the production of critically important intracellular antioxidants and other therapeutic compounds, today announced that its common shares are now trading on the OTCQX Best Market under the ticker symbol TTIPF. The OTCQX Best Market is the highest-level market of OTC Markets on which 12,000 U.S. and global securities trade. Trading on OTCQX...
2025-02-12 9:00 AM EST
Thiogenesis Receives Final EU Clearance of CTA to Initiate its Phase 2 Clinical Trial in MELAS
San Diego, California--(Newsfile Corp. - January 27, 2025) - Thiogenesis Therapeutics, and Corp. (TSXV: TTI) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing disulfides that drive the production of critically important intracellular antioxidants and other therapeutic compounds, today announced that the European Medicines Agency ("EMA") has accepted its Clinical Trial Application ("CTA") Part II - National and Patient Level Documentation, for Thiogenesis' lead compound TTI-0102. It is the final regulatory clearance required for Thiogenesis to commence its Phase 2...
2025-01-27 9:00 AM EST
Thiogenesis Announces Presentation on UMDF Webcast Featuring Clinical Trials in Mitochondrial Disease
San Diego, California--(Newsfile Corp. - December 10, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing novel thiol compounds, including precursors to cysteamine, that have potent antioxidant and anti-inflammatory properties for mitochondrial diseases and related metabolic conditions is pleased to announce that Patrice Rioux, MD, Ph.D., Thiogenesis' Chief Executive Officer, presented an update on the Company's two clinical programs in mitochondrial disease at the United Mitochondrial Disease Foundation's ("UMDF") Webcast entitled, "Bench-to-Bedside" ...
2024-12-10 9:00 AM EST
Thiogenesis Announces DTC Eligibility in the U.S. and Other Updates
San Diego, California--(Newsfile Corp. - November 28, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTC: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing novel thiol compounds, that includes precursors to cysteamine and that have potent antioxidant and anti-inflammatory properties for the treatment of inherited mitochondrial diseases and metabolic conditions, is pleased to announce that it has attained Depository Trust Company ("DTC") eligibility status in the U.S. DTC eligibility allows electronic settlement of the Company's common shares necessary to...
2024-11-28 9:00 AM EST
Thiogenesis Announces Important Core Patent Allowed in Europe
San Diego, California--(Newsfile Corp. - November 4, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing novel thiol compounds, including precursors to cysteamine that have potent antioxidant and anti-inflammatory properties for mitochondrial diseases and related metabolic conditions; is pleased to announce that one of its core patents titled, "Methods For The Treatment of Cysteamine Sensitive Disorders," has been allowed by the European Patent Office (European Patent No. 18858763.8). The...
2024-11-04 9:00 AM EST